Technological projects portfolio

Most medical decisions are based on in vitro diagnostic tests or immunoassays, i.e. on the detection of biomarkers in biological fluids (blood, urine, saliva, etc.).

These tests are also used to monitor the evolution of pathologies.

However, it is necessary to improve the sensitivity of certain tests in order to detect molecules that are not very highly concentrated, and thus difficult to detect, or that require invasive sampling techniques (spinal tap, for example).

The NLISA project is dedicated to the development of a new technology that will increase the sensitivity of in vitro diagnostic tests using luminescent nanoparticles with unique colloidal and optical characteristics.

More sensitive detection will allow earlier detection of illnesses based on already existing biomarkers, but also on new biomarkers that are emerging, available in low concentrations or in samples of small volumes.

The NLISA luminescent nanoparticles improve the sensitivity of in vitro diagnostic tests for point-of-care applications (rapid test when caring for the patient) and ultra-sensitive applications (in the laboratory) when screening for pathologies that are difficult to diagnose in various fields of medicine (oncology, cardiology, infectious diseases, auto-immune disorders, etc.).